Climb Bio (CLYM) Long-Term Investments (2021 - 2026)

Climb Bio has reported Long-Term Investments for 5 years, with the latest figure at $36.7 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 63.18% year-over-year to $36.7 million; the trailing twelve-month figure through Mar 2026 stood at $36.7 million (down 63.18% YoY), and the FY2025 full-year result was $59.6 million, down 3.31% from the prior year.
• Long-Term Investments for Q1 2026 stood at $36.7 million, down from $59.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $102.7 million in Q2 2025, with the low at $7.0 million in Q3 2022.
• Historically, Long-Term Investments has averaged $51.8 million across 4 years, with a median of $48.2 million in 2025.
• Annual changes were most pronounced in 2022 — Long-Term Investments plunged 70.53% — and 2025, when it surged 261.86%.
• Climb Bio's Long-Term Investments stood at $7.0 million in 2022, then soared by 785.07% to $61.6 million in 2024, then retreated by 3.31% to $59.6 million in 2025, then plunged by 38.33% to $36.7 million in 2026.
• The last three Long-Term Investments figures came in at $36.7 million (Q1 2026), $59.6 million (Q4 2025), and $88.9 million (Q3 2025), per Business Quant data.